| 16.09 16:03 | dpa-AFX: Quest Completes Acquisition Of Select Laboratory Assets From Allina Health |
| 16.09 15:01 | dpa-AFX: *QUEST DIAGNOSTICS CLOSES ACQUISITION OF SELECT LAB ASSETS FROM ALLINA HEALTH |
| 06.09 15:46 | dpa-AFX: Quest Diagnostics Morgan Stanley Global Healthcare Conference; Webcast At 10:45 AM ET |
| 26.08 14:51 | dpa-AFX: *QUEST DIAGNOSTICS CLOSES ACQUISITION OF LIFELABS |
| 21.08 15:26 | dpa-AFX: Quest Diagnostics To Buy University Hospitals' Outreach Laboratory Services |
| 21.08 14:58 | dpa-AFX: *QUEST DIAGNOSTICS EXPECTS TO CLOSE OUTREACH LABORATORY SERVICES BUSINESS DEAL IN Q4 |
| 21.08 14:57 | dpa-AFX: *QUEST DIAGNOSTICS TO BUY UNIVERSITY HOSPITALS' OUTREACH LABORATORY SERVICES BUSINESS; TERMS UNDISCLOSED |
| 15.08 01:58 | dpa-AFX: *QUEST DIAGNOSTICS (DGX) DECLARES QUARTERLY DIVIDEND OF $ 0.75 , RECORD DATE 10/4/2024 |
| 15.08 01:06 | dpa-AFX: *QUEST DIAGNOSTICS DECLARES QUARTERLY DIVIDEND OF $0.75/SHARE PAYABLE OCT. 4/ RECORD OCT. 4 |
| 23.07 13:34 | dpa-AFX: Quest Diagnostics Q2 24 Earnings Conference Call At 8:30 AM ET |
| 23.07 12:51 | dpa-AFX: *QUEST DIAGNOSTICS NOW SEES FY REVENUES OF $9.50 BLN-$9.58 BLN; EPS OF $7.57-$7.77 AND ADJ EPS OF $8.80-$9.00 |
| 23.07 12:49 | dpa-AFX: Quest Diagnostics Q2 Profit Decreases, But Beats Estimates |
| 23.07 12:46 | dpa-AFX: *QUEST DIAGNOSTICS Q2 REVENUES $2.40 BLN, UP 2.5% FROM LAST YEAR |
| 23.07 12:46 | dpa-AFX: *QUEST DIAGNOSTICS Q2 EPS $2.03; ADJ EPS $2.35 |
| 18.07 15:11 | dpa-AFX: Haystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer Therapy |
| 18.07 14:26 | dpa-AFX: *HAYSTACK ONCOLOGY AND LISATA THERAPEUTICS COLLABORATE TO EVALUATE PANCREATIC CANCER THERAPY |
| 10.07 15:18 | dpa-AFX: Quest Diagnostics To Acquire Outreach Laboratory Services Of OhioHealth |
| 10.07 15:03 | dpa-AFX: *QUEST DIAGNOSTICS TO BUY OUTREACH LABORATORY SERVICES OF OHIOHEALTH |
| 03.07 15:01 | dpa-AFX: Quest Diagnostics To Acquire LifeLabs From OMERS In About $985 Mln Deal |
| 03.07 14:50 | dpa-AFX: *QUEST DIAGNOSTICS EXPECTS TO COMPLETE LIFELABS DEAL BY END OF YEAR |
|
|
